World Health Organization Raises Warning Over Critical Lack of Obesity Injections
Less than a tenth of patients who could benefit from GLP-1 drugs such as Wegovy are able to get them, caution the global health agency as it releases its initial recommendations on the medications.
With in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for increased and just access to these injectable treatments.
According to forecasts, more than two billion are projected to be obese by 2030 if no action is taken.
"The new guidelines affirms that excess weight is a lifelong illness that can be managed with thorough and lifelong support," said its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are key obstacles to universal availability to the treatments that can help people shift significant weight, says the organization.
Skinny Jab Scarcity
Even in the present most optimistic scenario, the supply of these medications would only suffice for approximately 100 million people – less than 10% of the global need, per the health organization.
The advice urges governments and firms to increase availability, by strategies such as voluntary licensing.
The intellectual property rights on semaglutide – the main component of the drug Wegovy – is set to lapse in multiple countries in 2026.
The Way Obesity Jabs Operate
GLP-1 drugs mimick a biological compound to reduce digestion speed, reduce hunger and boost satiety so users consume fewer calories.
Patients typically see weight reduction within a few weeks of beginning the weekly injections.
Studies suggests users may see weight return within a year of stopping the medication, as their usual appetite resume.
To be overweight or obese raises your chance for experiencing medical conditions, like diabetes, cardiovascular issues, brain attack, and certain malignancies.
Excess weight concerns people in every country and was linked to 3.7 million deaths worldwide in 2024, per the health agency.
